This site is intended for healthcare professionals
Breast cancer
Future breast cancer care: ESMO Breast Cancer 2024

Transcript: Early breast cancer highlights presented at ESMO 2024

Last updated:6th Jun 2024
Published:6th Jun 2024

Professor Rupert Bartsch

All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.


We'll deliver several presentations on early stage breast cancer. The main focus always with ESMO breast is still educational, but there were clearly also interesting data, scientific data, in the early stage setting. So, one of the interesting presentations was by Matteo Lambertini, on the risk for recurrences in patients harbouring germline BRCA mutations with pregnancy after breast cancer, especially with a focus on reproductive technologies, assisted reproductive technologies. Nearly 5,000 patients included here, more than 500 with the pregnancy after breast cancer, and 170 of those with assisted reproduction technologies used. And there was no risk in recurrence seen, no increased risk for recurrence is seen. So that obviously shows that in this population, ARTs is safe, and that's important news for our patients. Other interesting data focused on the comparison of chemotherapy with endocrine therapy plus CDK4/6 inhibitors. For example, the CARABELA trial, randomised phase 2 trial comparing standard chemotherapy with 12 month of endocrine therapy and abemaciclib. And the primary endpoint here was the rate of RCBs or residual cancer burden, score zero. And one in both groups. And that was numerically superior in the chemotherapy arm. Also, the number of patients achieving a PEPI score of zero, so very low proliferation. That was higher in the chemotherapy arm. So at the moment it's not clear whether endocrine therapy plus CDK4/6 inhibitors can substitute chemotherapy for selected patients in the neoadjuvant setting. This is something that is still open and further larger trials are required.

View the video


Developed independently by EPG Health, which received educational funding from Pierre Fabre Medicament awarded to EPG Health to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.